Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma

scientific article published on 17 May 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/2159-8290.CD-18-0099
P932PMC publication ID6030433
P698PubMed publication ID29773717

P50authorMari Mino-KenudsonQ40930518
Lee AlbackerQ41706995
Kwok Kin WongQ42687956
Michael E. GoldbergQ56484229
Andrew J PlodkowskiQ57618034
Ignacio I WistubaQ74766086
Warren L DenningQ79287405
Achim A JungbluthQ87949473
Jedd D. WolchokQ88137705
John V HeymachQ88721314
Vassiliki PapadimitrakopoulouQ94475620
P2093author name stringJing Wang
Siraj M Ali
Charles M Rudin
Pasi A Jänne
Vincent A Miller
Philip J Stephens
Pan Tong
J Jack Lee
Jeffrey S Ross
Jianjun Zhang
Neda Kalhor
Lynette M Sholl
Fei Jiang
Stefan Kirov
Han Chang
Alexa B Schrock
Jaime Rodriguez-Canales
David R Spigel
Mizuki Nishino
Alice T Shaw
Nir Peled
William J Geese
Justin F Gainor
Laurie Gay
Garrett M Frampton
Julia A Elvin
Danielle M Greenawalt
David Fabrizio
Patrik Vitazka
Matthew D Hellmann
Mark M Awad
Brett W Carter
Roxana Azimi
Sujaya Srinivasan
Ferdinandos Skoulidis
Darragh F Halpenny
Niamh M Long
Gaurav Singal
Taghreed Hirz
Yasir Y Elamin
Neelesh Sharma
Jennifer L Sauter
Hira Rizvi
Giulia C Leonardi
Sally E Trabucco
Ariella Sasson
Ana Galan-Cobo
Sai-Hong I Ou
Edwin R Parra
Ryan J Hartmaier
Peter M Szabo
Jeremy Erasmus
Robin Edwards
Joseph Szustakowski
Pamela A Villalobos
Haifa Hamdi
Elizabeth Jimenez Aguilar
Jose A Bufill
P2860cites workFirst-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.Q39388286
Negative Regulation of TGFβ Signaling by the Kinase LKB1 and the Scaffolding Protein LIP1Q39640020
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Q40408396
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upQ40559745
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityQ40944056
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionQ41437712
The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 lossQ42705776
Myc Cooperates with Ras by Programming Inflammation and Immune SuppressionQ46758501
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingQ47163678
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical TrialQ47439995
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).Q47567375
Anchored multiplex PCR for targeted next-generation sequencingQ48254505
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic valueQ49389650
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasisQ50001731
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingQ50027697
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune ControlQ50076191
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeQ53769936
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung CancerQ89783904
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentQ26796305
Innate and adaptive immune cells in the tumor microenvironmentQ27008342
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesQ27345462
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialQ27853359
Comprehensive molecular profiling of lung adenocarcinomaQ28244995
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencingQ28275103
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerQ29615679
The LKB1-AMPK pathway: metabolism and growth control in tumour suppressionQ29617506
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsQ29617771
Genetic basis for clinical response to CTLA-4 blockade in melanomaQ29620594
Pembrolizumab for the treatment of non-small-cell lung cancerQ29620851
PD-1 blockade induces responses by inhibiting adaptive immune resistanceQ29620856
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerQ29620902
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerQ29620913
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Q30275719
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingQ30514084
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenQ33576170
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyQ34522172
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.Q34736608
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityQ35634752
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasQ35775729
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAQ35810461
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsQ35998823
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Q36553576
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patientsQ36746536
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanomaQ36865568
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaQ37319470
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Q38731119
LKB1 loss links serine metabolism to DNA methylation and tumorigenesisQ38733837
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cellsQ38766859
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Q38798543
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and BevacizumabQ39001187
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.Q39207634
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectadenocarcinomaQ356033
P304page(s)822-835
P577publication date2018-05-17
P1433published inCancer DiscoveryQ15724440
P1476titleSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
P478volume8

Reverse relations

cites work (P2860)
Q89561186A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Q92214286An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Q91838880Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
Q64882923Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Q64971607Are lung adenocarcinoma mutations shaping the immune microenvironment?
Q91820016Avelumab in non-small-cell lung cancer
Q89899863Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer
Q91754859Biomarker-guided therapy for colorectal cancer: strength in complexity
Q91136112Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
Q90091794Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
Q99603569Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective
Q92356109Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer
Q103803788CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
Q92819972Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
Q92659638Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Q98289165Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Q89751764Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
Q98177744Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective
Q90366349Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Q59793918Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
Q92578527Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Q99561280Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer
Q91341294Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Q89454232Comprehensive T cell repertoire characterization of non-small cell lung cancer
Q99582766Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Q98948996Current and future trends in non-small cell lung cancer biomarker testing: The American experience
Q61810141Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
Q90220319Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
Q93116739Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
Q58609277Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic
Q100316536Discovering functional evolutionary dependencies in human cancers
Q91386685Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation
Q90100630Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Q94591586Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
Q92156737Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis
Q58086856Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Q100490624Emerging role of tumor cell plasticity in modifying therapeutic response
Q104105690Enhancing anti-tumour efficacy with immunotherapy combinations
Q92608513Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Q100426629From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Q92179996Genomic correlates of response to immune checkpoint blockade
Q59800659Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Q59807014HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Q64107863Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas
Q89647127Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Q89940636Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
Q101051131Immune modulatory effects of oncogenic KRAS in cancer
Q58107915Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy
Q91908238Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
Q58575896Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Q92425244Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Q92716661Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer
Q64229216Implementing TMB measurement in clinical practice: considerations on assay requirements
Q92972168In the literature: April 2019
Q89965765Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Q64080812It's far better to be alone than to be in bad company
Q90612131KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
Q132041974KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry
Q91671471KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
Q89730893KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Q64120316KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Q64251353LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
Q132730488LKB1 expression and the prognosis of lung cancer
Q90639806Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Q98771234Mechanisms of Cancer Resistance to Immunotherapy
Q132044601Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
Q61810151Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
Q92709040Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Q64111039Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
Q94585672Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Q99417792Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Q92095000Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Q90706520New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Q99550699New biomarkers for checkpoint inhibitor therapy
Q94571772Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort
Q64993903Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.
Q64053621Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Q94526250Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Q92733969Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
Q132042503Posttranslational regulation of liver kinase B1 in human cancer
Q99630568Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Q90568070Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Q57191808Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Q61810152Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
Q91650557Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Q96302844RAS-targeted therapies: is the undruggable drugged?
Q89537473Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Q98466646Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Q64236786Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
Q91315092Roche splashes $2.4 billion on Foundation Medicine's cancer platform
Q96954202Role of DNA repair defects in predicting immunotherapy response
Q89753117STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Q97541018STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
Q132041488STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Q64946449Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Q57293747Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer
Q91235699Synthetic lethality as an engine for cancer drug target discovery
Q92702616Targeting Oncogenic BRAF: Past, Present, and Future
Q92048149Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Q92214297The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Q64374979The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Q90310543The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Q61810136The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients
Q101574526The cutting-edge progress of immune-checkpoint blockade in lung cancer
Q90242165The emerging role of epigenetic therapeutics in immuno-oncology
Q91520697The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Q103806134The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Q90372098The lung microenvironment: an important regulator of tumour growth and metastasis
Q90929632The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II
Q133054822Transcriptional regulation by LKB1 in lung adenocarcinomas: Exploring oxidative stress, neuroglial and amino acid signatures
Q90440514Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Q98564973Understanding genomics and the immune environment of penile cancer to improve therapy
Q132047569Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Q61810147Update on emerging biomarkers in lung cancer
Q64881720When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Q99547332Whole Exome Profiling of NSCLC Among African Americans

Search more.